The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact of KRAS, BRAF, and PIK3CA mutations, PTEN, AREG, and EREG expression, and skin rash in metastatic colorectal cancer patients treated with cetuximab-containing salvage treatment.
Zacharenia Saridaki
Disclosure not yet available
Maria Tzardi
Disclosure not yet available
Chara Papadaki
Disclosure not yet available
Maria Sfakianaki
Disclosure not yet available
Franka Pega
Disclosure not yet available
Aristea Kalikaki
Disclosure not yet available
Eleftheria Tsakalaki
Disclosure not yet available
Dimitrios Mavroudis
Disclosure not yet available
Vassilis Georgoulias
Disclosure not yet available
Ioannis Sougklakos
Disclosure not yet available